EFFICACY OF SACUBITRIL/VALSARTAN IN MANAGING HYPERTENSION AND REVERSING CARDIAC REMODELING IN MAINTENANCE HEMODIALYSIS PATIENTS

Cardiovascular diseases (CVD) account for over 50% of mortality rates among patients undergoing maintenance hemodialysis (HD).[1] In the terminal stages of chronic kidney disease (CKD), factors such as volume and pressure overload, neurohormonal imbalance, and chronic inflammation lead to structural changes in the myocardium, known as pathological cardiac remodeling. .[2] Specifically, left ventricular hypertrophy (LVH) and myocardial fibrosis significantly impair the quality of life for dialysis patients. .[3] In recent years, the administration of Sacubitril/Valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has opened new perspectives in managing these cardiorenal pathologies by activating the natriuretic peptide system. .[4]